Literature DB >> 19874199

Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors.

Stefania Piersanti1, Cristina Remoli, Isabella Saggio, Alessia Funari, Stefano Michienzi, Benedetto Sacchetti, Pamela Gehron Robey, Mara Riminucci, Paolo Bianco.   

Abstract

Human skeletal progenitors were engineered to stably express R201C mutated, constitutively active Gs alpha using lentiviral vectors. Long-term transduced skeletal progenitors were characterized by an enhanced production of cAMP, indicating the transfer of the fundamental cellular phenotype caused by activating mutations of Gs alpha. Like skeletal progenitors isolated from natural fibrous dysplasia (FD) lesions, transduced cells could generate bone but not adipocytes or the hematopoietic microenvironment on in vivo transplantation. In vitro osteogenic differentiation was noted for the lack of mineral deposition, a blunted upregulation of osteocalcin, and enhanced upregulation of other osteogenic markers such as alkaline phosphatase (ALP) and bone sialoprotein (BSP) compared with controls. A very potent upregulation of RANKL expression was observed, which correlates with the pronounced osteoclastogenesis observed in FD lesions in vivo. Stable transduction resulted in a marked upregulation of selected phosphodiesterase (PDE) isoform mRNAs and a prominent increase in total PDE activity. This predicts an adaptive response in skeletal progenitors transduced with constitutively active, mutated Gs alpha. Indeed, like measurable cAMP levels, the differentiative responses of transduced skeletal progenitors were profoundly affected by inhibition of PDEs or lack thereof. Finally, using lentiviral vectors encoding short hairpin (sh) RNA interfering sequences, we demonstrated that selective silencing of the mutated allele is both feasible and effective in reverting the aberrant cAMP production brought about by the constitutively active Gs alpha and some of its effects on in vitro differentiation of skeletal progenitors. (c) 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19874199      PMCID: PMC5524372          DOI: 10.1359/jbmr.091036

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  42 in total

1.  Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.

Authors:  L Persani; S Borgato; A Lania; M Filopanti; G Mantovani; M Conti; A Spada
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 2.  Quantification using real-time PCR technology: applications and limitations.

Authors:  Dieter Klein
Journal:  Trends Mol Med       Date:  2002-06       Impact factor: 11.951

Review 3.  Allele-specific RNA interference for neurological disease.

Authors:  E Rodriguez-Lebron; H L Paulson
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

4.  Mutations in the GTP-binding site of GS alpha alter stimulation of adenylyl cyclase.

Authors:  S B Masters; R T Miller; M H Chi; F H Chang; B Beiderman; N G Lopez; H R Bourne
Journal:  J Biol Chem       Date:  1989-09-15       Impact factor: 5.157

5.  Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers.

Authors:  A J Friedenstein; R K Chailakhyan; U V Gerasimov
Journal:  Cell Tissue Kinet       Date:  1987-05

6.  Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment.

Authors:  Benedetto Sacchetti; Alessia Funari; Stefano Michienzi; Silvia Di Cesare; Stefania Piersanti; Isabella Saggio; Enrico Tagliafico; Stefano Ferrari; Pamela Gehron Robey; Mara Riminucci; Paolo Bianco
Journal:  Cell       Date:  2007-10-19       Impact factor: 41.582

7.  Targeted expression of activated Q227L G(alpha)(s) in vivo.

Authors:  Xi-Ping Huang; Xiaosong Song; Hsien-Yu Wang; Craig C Malbon
Journal:  Am J Physiol Cell Physiol       Date:  2002-08       Impact factor: 4.249

8.  Cardiac Gsalpha overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway.

Authors:  A S Lader; Y F Xiao; Y Ishikawa; Y Cui; D E Vatner; S F Vatner; C J Homcy; H F Cantiello
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Activation of cyclic nucleotide phosphodiesterases in FRTL-5 thyroid cells expressing a constitutively active Gs alpha.

Authors:  G Nemoz; C Sette; M Hess; C Muca; L Vallar; M Conti
Journal:  Mol Endocrinol       Date:  1995-10

10.  Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.

Authors:  M Riminucci; L W Fisher; A Shenker; A M Spiegel; P Bianco; P Gehron Robey
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

View more
  38 in total

1.  "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease.

Authors:  Paolo Bianco; Pamela Gehron Robey; Isabella Saggio; Mara Riminucci
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.

Authors:  Sunday O Akintoye; Alison M Boyce; Michael T Collins
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-09

Review 3.  PTH and stem cells.

Authors:  M Ohishi; E Schipani
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

4.  Denosumab treatment for fibrous dysplasia.

Authors:  Alison M Boyce; William H Chong; Jack Yao; Rachel I Gafni; Marilyn H Kelly; Christine E Chamberlain; Carol Bassim; Natasha Cherman; Michelle Ellsworth; Josephine Z Kasa-Vubu; Frances A Farley; Alfredo A Molinolo; Nisan Bhattacharyya; Michael T Collins
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

Review 5.  Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.

Authors:  Cemre Robinson; Michael T Collins; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 6.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

Review 7.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

8.  Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.

Authors:  Pablo Florenzano; Kristen S Pan; Sydney M Brown; Scott M Paul; Harvey Kushner; Lori C Guthrie; Luis Fernandez de Castro; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-01-15       Impact factor: 6.741

Review 9.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

10.  Loss of Gsα early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors.

Authors:  Partha Sinha; Piia Aarnisalo; Rhiannon Chubb; Noriaki Ono; Keertik Fulzele; Martin Selig; Hamid Saeed; Min Chen; Lee S Weinstein; Paola Divieti Pajevic; Henry M Kronenberg; Joy Y Wu
Journal:  J Bone Miner Res       Date:  2014-11       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.